Integrating digital PCR, specialized virology expertise, high-throughput automated workflows, culture-based approaches, and a CLIA laboratory to develop scalable and reproducible assays.
Our assays for target quantitation are critical components of cure programs for HIV-1 and infectious diseases. Accelevir and their collaborators have dedicated their lives to developing curative and targeted medicines for infectious diseases. Our novel assays are optimized to enable clinicians, researchers, and customers to access reproducible and highly quantitative tests.
Partnerships & Collaboration
Advancing next generation therapeutics is a team effort and Accelevir is committed to supporting our partners with innovative and scalable assay solutions. The convergence of scientific and operational capabilities enable us to support our partner development programs.
Clinical Trials & Clinicians
As a CLIA-certified, high-complexity molecular testing laboratory, we support the development, validation, implementation of In Vitro Diagnostics (IVD) and Laboratory Developed Tests (LDTs) across a variety of platforms.
We are led by science, high integrity and social responsibility.
Who We Are
Accelevir is a Maryland-based biotechnology company developing and enabling innovative assays for ultra-rare analytes. We are driven by a strong scientific ethos with continual advancement of our operational standards. We advance disruptive technologies to market for enabling cure programs.
We employ a highly collaborative model to continually expand our products and services.
Join the Team Leading the Change
We are looking for talented and creative problem solvers who are passionate about developing and performing assays to improve human health.